Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304858 · ClinicalTrials.gov registry record
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
A clinical trial of Recurrent Prostate Cancer, sponsored by Columbia University.
- Recruiting
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT05304858: Recruiting study of Recurrent Prostate Cancer, sponsored by Columbia University.
NCT05304858 is a study of Recurrent Prostate Cancer that is actively recruiting participants, run by Columbia University. The registered enrollment target is 16 participants, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05304858, a study of Recurrent Prostate Cancer, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect prostate cancer tissue from males with metastatic prostate cancers in order to study the tumor microenvironment (TME), which is the area surrounding the tumor including cells, blood vessels, etc., in men with metastatic prostate cancer. The type of research performed on these tissue samples include genetic \& molecular analyses.
Primary Outcome
Profiling of the tumor microenvironment (TME) through single-cell RNA sequencing (scRNAseq) for deep profiling of the local immune microenvironment in the tumor.
Conditions Studied
Interventions
- PROCEDURE Biopsy
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2028-02 |
What NCT05304858 shows while recruiting
NCT05304858 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.
NCT05304858 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05304858 about?
NCT05304858 is a clinical study titled "Tumor Microenvironment Analysis of Prostate Cancer Metastasis". The purpose of this study is to collect prostate cancer tissue from males with metastatic prostate cancers in order to study the tumor microenvironment (TME), which is the area surrounding the tumor including cells, blood vessels, etc., in men with metastatic prostate cancer. The type of research pe...
What is the current status of trial NCT05304858?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2021-09-15. Estimated completion is 2028-02.
What conditions does trial NCT05304858 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer.
What interventions are being tested in trial NCT05304858?
The interventions under investigation include: Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05304858?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05304858 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05304858's enrollment target sits among peer trials
16 19th of 21 higher than 3 of 21 other Recurrent Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI